Breaks Categories: News

ThursdayAug 14, 2025 1:46 pm

NetworkNewsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Signs LOI for Exclusive Nimbus Boats Distribution on Florida’s West Coast

Vision Marine Technologies (NASDAQ: VMAR), a leader in premium on-water experiences and owner of Florida-based dealership network Nautical Ventures, announced Nautical Ventures has signed a Letter of Intent with Nimbus Boats USA to exclusively distribute Nimbus powerboats on Florida’s West Coast. The agreement, expected to be finalized by March 31, 2026, would authorize Nautical Ventures to promote, sell and service Nimbus’s Tender, Commuter, Weekender and Coupe series beginning August 1, 2025. The move aims to broaden Vision Marine’s product portfolio, strengthen its Florida presence and capture demand in the fast-growing adventure-style boat segment. Florida remains the largest U.S. market for…

Continue Reading

ThursdayAug 14, 2025 1:23 pm

NetworkNewsBreaks – ECGI Holdings Inc. (OTC: ECGI) Invests in AI Sales and Marketing Platform AuraChat Ahead of Major Product Launch 

ECGI Holdings (OTC: ECGI), announced that its investment arm, Uplist Ventures, has made a strategic investment in AuraChat.ai, a sales and marketing automation platform powered by more than 25 proprietary AI models. The deal comes ahead of AuraChat’s planned September 2025 launch of AuraConnect™ 2.0, a competitive-intelligence upgrade expanding into sectors including automotive, real estate, and retail. AuraChat provides AI-driven voice, video, and messaging solutions in over 50 languages, delivering 24/7 customer service, lead follow-up, scheduling, and analytics. With nearly $400,000 in annual recurring revenue and recognition as one of UCLA Anderson School of Business’s Top 10 Startups, the company’s…

Continue Reading

ThursdayAug 14, 2025 12:01 pm

NetworkNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Q2 2025 Results Show Record First-Half Profitability, Strong U.S. Contract Wins

SuperCom (NASDAQ: SPCB), a global provider of secured e-Government, IoT, and cybersecurity solutions, reported Q2 2025 revenue of $7.14 million, with gross margin rising to 59.1% from 49.6%. Q2 operating income grew 187% to $1.1 million, while EBITDA rose 56% to $2.5 million. First-half 2025 net income climbed 79.5% to $5.3 million on gross margin expansion to 61.2% and doubled operating margins. The company ended Q2 with $15 million in cash and working capital of $40.8 million. Recent wins include over 30 new U.S. electronic monitoring contracts since mid-2024—expanding into 11 states—and national projects in EMEA. Management said strong execution,…

Continue Reading

ThursdayAug 14, 2025 11:00 am

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Webull Financial Biotech/MedTech Webinar Series

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharma company developing novel treatments for primary and metastatic cancers in the brain and central nervous system, announced it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, taking place virtually Aug. 19–21, 2025. To view the full press release, visit https://nnw.fm/NzZ1Q About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis…

Continue Reading

ThursdayAug 14, 2025 10:50 am

NetworkNewsBreaks – FingerMotion Inc. (NASDAQ: FNGR) Showcases Emergency Command Platform at Indonesia Disaster Expo

FingerMotion (NASDAQ: FNGR) announced that its subsidiary, Shanghai JiuGe Information Technology Co., Ltd., is presenting its Advanced Mobile Integrated Command and Communication Platform (C2 Platform) at the 2nd Indonesia International Emergency, Disaster Reduction and Rescue Expo, held Aug. 13–15, 2025, in Jakarta. The system integrates satellite communications, high-definition video, intelligent conferencing, UAV capabilities, and multi-network connectivity to enable uninterrupted command during crises, even without public networks. Already deployed in emergency vehicles across several Chinese cities, the platform has attracted interest from Indonesia’s National Disaster Management Agency and National Search and Rescue Agency. FingerMotion said the event marks a key step…

Continue Reading

ThursdayAug 14, 2025 10:48 am

NetworkNewsBreaks – Newton Golf Company Inc. (NASDAQ: NWTG) Q2 2025 Revenue Jumps 154% on Strong Demand for Motion and Fast Motion Shafts

Newton Golf Company (NASDAQ: NWTG), a technology-forward golf company delivering physics-based performance innovations, reported Q2 2025 revenue of $2.1 million, up 154% from $813,000 in the year-ago quarter, with gross margin improving to 67.6% from 60.1%. First-half 2025 revenue rose 182% to $3.3 million, while net loss narrowed to $2.1 million from $2.4 million. The company cited rapid adoption of its new Fast Motion shaft—launched April 29—which generated more than $696,000 in gross sales in its first two months and has already surpassed 2,200 units sold in Q3. Additional highlights included surpassing 50 professional users across major tours, expanding global…

Continue Reading

ThursdayAug 14, 2025 10:15 am

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results, Targets Year-End NDA Submission for ALS Therapy

Clene (NASDAQ: CLNN), a late clinical-stage biopharma company developing treatments for neurodegenerative diseases, reported Q2 2025 results and said it has sufficient cash runway into Q1 2026. The company plans to meet with the FDA this quarter to review survival data for lead candidate CNM-Au8 in amyotrophic lateral sclerosis (ALS) and is preparing analyses of NIH-sponsored Expanded Access Program neurofilament light biomarker data, expected in Q4. These steps are intended to support a potential New Drug Application submission under the FDA’s accelerated approval pathway for ALS by year-end 2025. Management said its focus remains on delivering an impactful therapy to the…

Continue Reading

ThursdayAug 14, 2025 10:10 am

NetworkNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q2 2025 Results, Achieves Complete Responses in Multiple Trials, Expands AI Platform

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharma company leveraging its RADR(R) AI/ML platform for oncology drug discovery and development, announced Q2 2025 results and portfolio updates. The company reported complete responses in patients across two trials — LP-300 in advanced NSCLC and LP-284 in refractory diffuse large B-cell lymphoma — along with completion of LP-184 Phase 1a enrollment, positioning it for Phase 1b/2 studies in high-value indications. LP-184 has FDA Fast Track and multiple Rare Pediatric Disease designations and showed significant survival gains in ATRT models. Lantern strengthened its IP with a European patent allowance for LP-284 and publication of…

Continue Reading

ThursdayAug 14, 2025 9:25 am

NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Q2 2025 Results Highlight Progress in Late-Stage Rare Disease Pipeline

Soligenix (NASDAQ: SNGX), a late-stage biopharma company developing treatments for rare diseases, reported Q2 2025 results and recent milestones. The company expects top-line Phase 2a results for SGX302 in mild-to-moderate psoriasis before year-end, along with continued updates from its investigator-initiated study of HyBryte(TM) for early-stage cutaneous T-cell lymphoma (CTCL). A confirmatory Phase 3 trial of HyBryte(TM) in early-stage CTCL is actively enrolling, with results anticipated in 2026. Soligenix also completed a Phase 2a proof-of-concept study of SGX945 for Behçet’s Disease, achieving its primary objective of demonstrating biological efficacy, and transferred manufacturing of synthetic hypericin to the U.S. under its Sterling…

Continue Reading

ThursdayAug 14, 2025 9:00 am

NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Q2 2025 Results, Advances Toward FDA Clearance and Commercial Launch

HeartBeam (NASDAQ: BEAT), a medical technology company developing personalized cardiac care solutions, reported financial and operational results for the quarter ended June 30, 2025. The company said it remains on track to receive FDA 510(k) clearance for its 12-lead ECG synthesis software for arrhythmia assessment by year-end, following positive pivotal study results showing 93.4% diagnostic agreement with standard 12-lead ECGs. HeartBeam is executing commercial readiness plans, including establishing manufacturing, logistics, and cardiologist review services, with launch expected after clearance. Additional highlights include an accepted AI algorithm abstract for HRX Live 2025, issuance of a new international patent bringing the total…

Continue Reading